Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Dec 19, 2026 → Dec 19, 2028
See other at-risk trials from Massachusetts General Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Dec 19, 2026 to Dec 19, 2028 Show 5 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 3 of 3 entries
    • Publications: details revised at 37 of 37 entries
    • Study description expanded, about 5 words
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
A total of fifty-five (55) patients with liver cirrhosis will be enrolled in this study to produce and validate dedicated Ga-PSMA-PET/MRI acquisition protocols. The specific hypotheses include: * Ga-PSMA PET/MRI may allow robust and reproducible noninvasive in vivo quantitation of hepatic macro and microhemodynamics in cirrhotic patients * Dedicated simultaneously acquired DWI sequences might quantitate liver fibrosis and improve hemodynamic quantitation. * Ga-PSMA PET/MRI may allow noninvasive and reproducible quantitation of portal venous hypertension and predict its evolution, as well as response to treatments * Ga-PSMA PET/MRI may improve noninvasive and reproducible qualitative and quantitative assessment of liver function, structure, nodules and predict evolution of cirrhosis
Trial Details
NCT Number NCT06265272
Lead Sponsor Massachusetts General Hospital
Conditions
(from sponsor)		 Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension
Related terms Carcinoma, Hepatocellular, Fibrosis, Hypertension, Portal, Liver Cirrhosis
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov